• Price (EUR)69.60
  • Today's Change0.32 / 0.46%
  • Shares traded57.61k
  • 1 Year change+26.64%
  • Beta-0.0972
Data delayed at least 15 minutes, as of Dec 07 2022 16:35 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Pharma Mar SA is a Spain-based integrated biopharmaceutical company focused on oncology and committed to research and development (R&D) of antitumor drugs of marine origin. The Company, through its subsidiaries, operates three business segments: Oncology, Diagnostics and RNA interference. The Oncology segment encompasses research, develop and market anti-tumor drugs. The Diagnostics segment includes the development and marketing of diagnostic kits. The RNA interference segment consist of the development of drugs with therapeutic activity based on reducing or silencing gene expression. The Company’s product portfolio includes Yondelis and ZEPZELCA. Yondelis (trabectedin) is indicated for the treatment of advanced soft tissue sarcoma, as well as for the treatment of relapsed platinum-sensitive ovarian cancer. ZEPZELCA (lurbinectedin) is indicated for the treatment of metastatic small cell lung cancer (SCLC) with disease progression. The Company is active globally.

  • Revenue in EUR (TTM)227.29m
  • Net income in EUR86.13m
  • Incorporated1986
  • Employees477.00
  • Location
    Pharma Mar SAAvda. De los Reyes, 1, Pol. Ind. La MinaCOLMENAR VIEJO 28770SpainESP
  • Phone+34 918466000
  • Fax+34 918466001
  • Websitehttps://www.pharmamar.com/es/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Fagron NV625.79m69.41m925.55m3.06k13.342.499.241.480.95080.95088.575.100.71363.5010.55204,438.407.957.309.939.9842.1844.0511.1410.411.2314.060.527812.973.216.352.35--7.01--
Valneva SE393.81m-158.52m926.84m700.00--8.4343.812.35-1.45-1.453.720.79520.53572.9422.99545,440.40-21.56-8.98-54.93-12.9217.5753.98-40.25-18.410.9368-4.480.5888--215.5229.91-14.03--90.83--
Puretech Health PLC17.75m-12.90m930.78m95.00--1.73--52.44-0.0386-0.03860.05331.670.0216--4.76161,160.70-1.004.86-1.266.24-----46.43260.53----0.07710.0047.7631.45-1,111.83--9.02--
Vetoquinol SA536.71m48.07m1.00bn2.55k20.802.1512.261.874.064.0645.3639.240.8752.345.43210,803.207.826.9710.289.1849.2561.108.948.781.151,370.760.040815.1521.948.27227.0417.7018.9713.22
EIS Eczcb Ilc Sn ve Fn Ytm Sny ve Tct AS73.60m47.87m1.01bn352.0021.132.5520.5213.751.361.362.1011.300.19366.627.064,273,170.0012.596.4313.576.9334.7934.3765.0538.822.83--0.027745.9221.3815.79134.4328.21-10.22-10.20
Eckert & Zieglr Strahln und Mdzntchnk AG213.44m28.61m1.04bn945.0035.715.1126.874.861.371.3710.239.590.59512.446.11246,463.008.118.389.6010.1349.6747.8413.6212.772.3453.280.184835.572.445.5262.2027.0840.1724.82
Cosmo Pharmaceuticals NV78.15m35.28m1.10bn292.0033.322.2322.8414.121.861.864.2927.830.11772.923.81265,696.905.32-2.095.51-2.1653.4359.6445.17-19.0510.81--0.268--6.77-0.7776374.292.30-14.33--
FAES Farma SA436.76m85.99m1.13bn1.66k13.12--10.752.580.27660.27661.38--------262,951.20--12.75--15.0763.3363.5119.7218.09--------4.8211.7614.6217.8437.7518.23
AddLife AB815.77m54.75m1.20bn2.20k22.712.8110.251.474.874.8772.6439.400.76933.966.524,932,631.
Formycon AG38.98m76.73m1.25bn178.0013.363.1415.9832.,935.7017.17-6.5917.81-7.3931.9729.53197.04-8.862.12--0.0456--20.3516.22-127.42---2.05--
Pharma Mar SA227.29m86.13m1.27bn477.0014.525.9013.915.594.774.5212.5811.750.62550.78618.24476,496.8023.7016.0431.0124.7094.4691.1837.8920.582.72--0.1612---14.874.90-32.35--5.07--
Zealand Pharma A/S13.52m-131.21m1.37bn203.00--24.86--100.97-22.13-25.892.277.910.07310.10021.76283,371.80-70.93-27.88-88.11-32.4994.20---970.30-275.483.69--0.575---69.28-14.0110.84--53.47--
Camurus AB79.95m2.61m1.37bn170.00560.7515.44365.5017.170.48150.481515.5517.490.76430.93196.595,885,939.002.50-27.663.09-33.8288.1386.733.27-84.903.0347.330.0253--78.7439.4945.93--1.59--
Biotest AG505.00m-70.89m1.53bn2.07k--2.48--3.03-3.58-3.5825.5217.380.4561.503.58256,736.10-6.25-2.44-6.92-2.8315.7427.69-13.70-5.862.09-5.090.6138--6.484.79-101.96---32.84--
Euroapi SAS943.90m2.00m1.61bn3.34k1,075.711.4420.001.710.01590.015910.3011.83------282,435.70--------16.44--0.2225--1.0511.330.0363---5.48---150.79------
Almirall SA843.74m18.72m1.71bn1.79k91.401.2540.232.020.10280.10284.607.520.3721.466.30472,417.100.8255-0.73840.9264-0.864578.1877.532.22-2.241.715.610.2104--2.451.59-155.01---2.82--
Data as of Dec 07 2022. Currency figures normalised to Pharma Mar SA's reporting currency: Euro EUR

Institutional shareholders

7.36%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 04 Nov 2022375.39k2.02%
Norges Bank Investment Managementas of 31 Dec 2021237.56k1.28%
BlackRock Fund Advisorsas of 03 Nov 2022188.27k1.02%
Goldman Sachs Asset Management LPas of 28 Feb 2021115.49k0.62%
Santander Asset Management SA SGIICas of 30 Sep 2022109.54k0.59%
Dimensional Fund Advisors LPas of 04 Nov 202281.02k0.44%
Credit Suisse AGas of 30 Sep 202268.42k0.37%
BlackRock Advisors (UK) Ltd.as of 03 Nov 202266.99k0.36%
Jupiter Asset Management Ltd.as of 31 Aug 202263.91k0.34%
MainFirst Affiliated Fund Managers (Deutschland) GmbHas of 30 Jul 202158.44k0.32%
More ▼
Data from 31 Dec 2021 - 30 Sep 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.